Changes in neurocognitive function in patients with schizophrenia after starting or switching to amisulpride in comparison with the normal controls

Yong Min Ahn, Kyu Young Lee, Chul Eung Kim, Jae-Jin Kim, Dae Yeob Kang, Tae Youn Jun, Jin Sook Choi, In Won Chung, Se Hyun Kim, Samuel S.H. Hwang, Yong Sik Kim

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

We examined short- and long-term changes in neurocognitive functions in patients with schizophrenia who were either started or switched to amisulpride in comparison with the normal controls. Fifty-seven patients treated with amisulpride and 60 normal controls completed a comprehensive neurocognitive function test battery at the baseline, the 8-week, and the 1-year follow-up. We conducted and compared the results of both intention-to-treat (ITT) and per-protocol (PP) analyses to account for the follow-up loss. Three general results obtained were as follows: (1) the degree of the improvements in neurocognitive function was comparable to those of other second-generation antipsychotics in both ITT and PP analysis; (2) in light of the relative effect size, the composite effect size and the effect size in most measures in both ITT and PP analyses were smaller for the patient group than those of the control group, signifying that improvement in performance may be largely attributable to practice effects; and (3) nonetheless, there were evidences of both short- and long-term improvements in some cognitive tasks, such as in the Korean-Wechsler Adult Intelligence Scale vocabulary subtest and the Trail Making Test, that may not be accounted by practice effect. These results suggest the need to include a healthy control group to validate the medication effect of cognitive improvements in patients with schizophrenia and to consider practice effect in interpreting the results of repeated administration of neurocognitive function tests.

Original languageEnglish
Pages (from-to)117-123
Number of pages7
JournalJournal of Clinical Psychopharmacology
Volume29
Issue number2
DOIs
Publication statusPublished - 2009 Apr 1

Fingerprint

Schizophrenia
Trail Making Test
Control Groups
Vocabulary
Intelligence
Antipsychotic Agents
sultopride

All Science Journal Classification (ASJC) codes

  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this

Ahn, Yong Min ; Lee, Kyu Young ; Kim, Chul Eung ; Kim, Jae-Jin ; Kang, Dae Yeob ; Jun, Tae Youn ; Choi, Jin Sook ; Chung, In Won ; Kim, Se Hyun ; Hwang, Samuel S.H. ; Kim, Yong Sik. / Changes in neurocognitive function in patients with schizophrenia after starting or switching to amisulpride in comparison with the normal controls. In: Journal of Clinical Psychopharmacology. 2009 ; Vol. 29, No. 2. pp. 117-123.
@article{3fc95db1b155475da8a6f32a9d45001b,
title = "Changes in neurocognitive function in patients with schizophrenia after starting or switching to amisulpride in comparison with the normal controls",
abstract = "We examined short- and long-term changes in neurocognitive functions in patients with schizophrenia who were either started or switched to amisulpride in comparison with the normal controls. Fifty-seven patients treated with amisulpride and 60 normal controls completed a comprehensive neurocognitive function test battery at the baseline, the 8-week, and the 1-year follow-up. We conducted and compared the results of both intention-to-treat (ITT) and per-protocol (PP) analyses to account for the follow-up loss. Three general results obtained were as follows: (1) the degree of the improvements in neurocognitive function was comparable to those of other second-generation antipsychotics in both ITT and PP analysis; (2) in light of the relative effect size, the composite effect size and the effect size in most measures in both ITT and PP analyses were smaller for the patient group than those of the control group, signifying that improvement in performance may be largely attributable to practice effects; and (3) nonetheless, there were evidences of both short- and long-term improvements in some cognitive tasks, such as in the Korean-Wechsler Adult Intelligence Scale vocabulary subtest and the Trail Making Test, that may not be accounted by practice effect. These results suggest the need to include a healthy control group to validate the medication effect of cognitive improvements in patients with schizophrenia and to consider practice effect in interpreting the results of repeated administration of neurocognitive function tests.",
author = "Ahn, {Yong Min} and Lee, {Kyu Young} and Kim, {Chul Eung} and Jae-Jin Kim and Kang, {Dae Yeob} and Jun, {Tae Youn} and Choi, {Jin Sook} and Chung, {In Won} and Kim, {Se Hyun} and Hwang, {Samuel S.H.} and Kim, {Yong Sik}",
year = "2009",
month = "4",
day = "1",
doi = "10.1097/JCP.0b013e31819a6995",
language = "English",
volume = "29",
pages = "117--123",
journal = "Journal of Clinical Psychopharmacology",
issn = "0271-0749",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

Changes in neurocognitive function in patients with schizophrenia after starting or switching to amisulpride in comparison with the normal controls. / Ahn, Yong Min; Lee, Kyu Young; Kim, Chul Eung; Kim, Jae-Jin; Kang, Dae Yeob; Jun, Tae Youn; Choi, Jin Sook; Chung, In Won; Kim, Se Hyun; Hwang, Samuel S.H.; Kim, Yong Sik.

In: Journal of Clinical Psychopharmacology, Vol. 29, No. 2, 01.04.2009, p. 117-123.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Changes in neurocognitive function in patients with schizophrenia after starting or switching to amisulpride in comparison with the normal controls

AU - Ahn, Yong Min

AU - Lee, Kyu Young

AU - Kim, Chul Eung

AU - Kim, Jae-Jin

AU - Kang, Dae Yeob

AU - Jun, Tae Youn

AU - Choi, Jin Sook

AU - Chung, In Won

AU - Kim, Se Hyun

AU - Hwang, Samuel S.H.

AU - Kim, Yong Sik

PY - 2009/4/1

Y1 - 2009/4/1

N2 - We examined short- and long-term changes in neurocognitive functions in patients with schizophrenia who were either started or switched to amisulpride in comparison with the normal controls. Fifty-seven patients treated with amisulpride and 60 normal controls completed a comprehensive neurocognitive function test battery at the baseline, the 8-week, and the 1-year follow-up. We conducted and compared the results of both intention-to-treat (ITT) and per-protocol (PP) analyses to account for the follow-up loss. Three general results obtained were as follows: (1) the degree of the improvements in neurocognitive function was comparable to those of other second-generation antipsychotics in both ITT and PP analysis; (2) in light of the relative effect size, the composite effect size and the effect size in most measures in both ITT and PP analyses were smaller for the patient group than those of the control group, signifying that improvement in performance may be largely attributable to practice effects; and (3) nonetheless, there were evidences of both short- and long-term improvements in some cognitive tasks, such as in the Korean-Wechsler Adult Intelligence Scale vocabulary subtest and the Trail Making Test, that may not be accounted by practice effect. These results suggest the need to include a healthy control group to validate the medication effect of cognitive improvements in patients with schizophrenia and to consider practice effect in interpreting the results of repeated administration of neurocognitive function tests.

AB - We examined short- and long-term changes in neurocognitive functions in patients with schizophrenia who were either started or switched to amisulpride in comparison with the normal controls. Fifty-seven patients treated with amisulpride and 60 normal controls completed a comprehensive neurocognitive function test battery at the baseline, the 8-week, and the 1-year follow-up. We conducted and compared the results of both intention-to-treat (ITT) and per-protocol (PP) analyses to account for the follow-up loss. Three general results obtained were as follows: (1) the degree of the improvements in neurocognitive function was comparable to those of other second-generation antipsychotics in both ITT and PP analysis; (2) in light of the relative effect size, the composite effect size and the effect size in most measures in both ITT and PP analyses were smaller for the patient group than those of the control group, signifying that improvement in performance may be largely attributable to practice effects; and (3) nonetheless, there were evidences of both short- and long-term improvements in some cognitive tasks, such as in the Korean-Wechsler Adult Intelligence Scale vocabulary subtest and the Trail Making Test, that may not be accounted by practice effect. These results suggest the need to include a healthy control group to validate the medication effect of cognitive improvements in patients with schizophrenia and to consider practice effect in interpreting the results of repeated administration of neurocognitive function tests.

UR - http://www.scopus.com/inward/record.url?scp=67649369293&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649369293&partnerID=8YFLogxK

U2 - 10.1097/JCP.0b013e31819a6995

DO - 10.1097/JCP.0b013e31819a6995

M3 - Article

VL - 29

SP - 117

EP - 123

JO - Journal of Clinical Psychopharmacology

JF - Journal of Clinical Psychopharmacology

SN - 0271-0749

IS - 2

ER -